Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-11
2006-04-11
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S355000, C514S438000, C514S466000, C514S518000, C514S604000, C544S131000, C544S405000, C546S291000, C546S316000, C546S332000, C548S336100, C548S495000, C548S537000, C548S561000, C548S566000, C549S065000, C549S078000, C549S441000, C549S493000, C558S058000, C564S092000
Reexamination Certificate
active
07026339
ABSTRACT:
The present invention relates to compounds, process for their synthesis, compositions and methods for the treatment and prevention of hepatitis C virus (HCV) infection. In particular, the present invention provides novel compounds, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment or prevention of HCV infection. The present invention also provides processes and intermediates for the synthesis of these compounds.
REFERENCES:
patent: 6930106 (2005-08-01), Finzel et al.
patent: WO 98/33501 (1998-08-01), None
patent: WO 00/06529 (2000-02-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 01/77091 (2001-10-01), None
patent: WO 02/04425 (2002-01-01), None
De Francesco et al., Antiviral Research, 58(10, Mar. 1-16, 2003.
Bilfin, Chemical Abstracts, 72:111251, 1970.
Burlov et al., Chemical Abstracts, 117:203959, 1992.
Aldred, R., et al., “Magnesium-Mediated Ortho-Specific Formylation And Formaldoximation Of Phenols,”J. Chem. Soc. Perkin Trans 1, 1994, 1823-1832, vol. 13.
Behrens, S., et al., “Identification And Properties Of The RNA-Dependent RNA Polymerase Of Hepatitis C Virus,”The EMBO Journal, 1996, 12-22, vol. 15, No. 1.
Berge, S., et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences, 1977, 1-19, vol. 66, No. 1.
Casiraghi, G., et al., “Selective Reactions Between Phenols And Formaldehyde. A Novel Route To Salicylaldehydes,”J. Chem. Soc. Perkins Trans. 1., 1980, 1862-1865.
Ferrari, E., et al., “Characterization Of Soluble Hepatitis C Virus RNA-Dependent RN Polymerase Expressed InEscherichia Coli,”Journal of Virology, 1999, 1649-1654, vol. 73n No. 2.
Guilbert, C. et al., “Isolation And Characterization Of The Fluorescent Alkali Product From Diphosphopyridine Nucleotide*,”Biochemistry, 1971, 2313, vol. 10, No. 12.
Hepworth, J., et al., “Synthesis And Reactions Of Some Chloro-2,2-Dimethylchromens,”Tetrahedron, 1981, 2613-2616, vol. 37, No. 15.
Houghton, M., et al.,Hepatitis C Viruses Fields Virology, Third Edition, 1996, 1035-1058, Edited By B. N. Fields, D. M. Knipe, P. M. Howley, et al., Lippincott-Raven Publishers, Philadelphia.
Ishido, S., et al., “Complex Formation Of NS5B With NS3 And NS4A Proteins Of Hepatitis C Virus,”Biochamical. And Biophysical Researc Communications, 1998, 35-40, vol. 244.
Kato, N., et al., “Molecular Cloning Of The Human Hepatitis C Virus Genome From Japanese Patients With Non-A, Non-B Hepatitis,”Proc. Natl. Acad. Sci., USA, 1990, 9524-9528, vol. 87.
Komiyama, M., et al., “Selective Syntheses Using Cyclodextrin As Catalyst. 1. Control Of Orientation In The Attack Of Dichlorocarene At Phenolates,”J. Amer. Chem. Soc., 1983, 2018-2021, vol. 105.
Lau, J., et al., “Application Of Six Hepatitis C Virus Genotyping Systems To Sera From Chronic Hepatitis C Patients In The United States,”The Journal of Infectious Diseases, 1995, 281-289, vol. 171, No. 2.
Lohmann, V., et al., “Biochemical Properties Of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase And Identification Of amino Acid Sequence Motifs Essential For Enzymatic Activity,”Journal of Virology, 1997, 8416-8428, vol. 71, No. 11.
Van Dorn, L., et al., “Review: Molecular Biology Of The Hepatitis C Virus,”Journal of Medical Virology, 1994, 345-356, vol. 43.
Wang, P., et al., “Design, Synthesis, Testing, And Quantitative Structure-Activity Relationship Analysis Of Substituted Salicylaldehyda Schiff Bases Of 1-Amino-3-Hydroxyguanidine Tosylate As new Antiviral Agents Coronavirus,”J. Med. Chem., 1990, 608-614, vol. 33, No. 2.
Webster, G., et al., “HCV Genotypes-Role In Pathogenesis Of Diseases And Response To Therapy,”Balliere's Clinical Gastroenterology, 2000, 229-240, vol 14, No. 2.
Anderson Rebecca Merry
Chen Ke
Funk Lee A.
Greene Meredith L.
Heier, III Richard Frederick
Powers Fiona T.
Tidwell Jeffrey H.
Zielinski Bryan C.
LandOfFree
Inhibitors of HCV NS5B polymerase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of HCV NS5B polymerase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of HCV NS5B polymerase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3530639